MabVax Therapeutics Holdings Inc
MabVax Therapeutics — Investor Presentation (June 2017)
23 slides from MabVax Therapeutics's investor presentation, Jun 23, 2017

Slide 1: MabVax Therapeutics Corporate Presentation June 2017
\y/ MabVax therapeutics Corporate Presentation June 2017 NASDAQ: MBVX ‘wirenabvatlae

Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements and projections. The company makes no express or implied representation or warranty as to the completeness of this information or, inthe case of the projections, as to their attainabilty or the accuracy and completeness

Slide 3: Table of Contents
M Table of Contents + Company Overview + Management Team & Board of Directors * Discovery Platform + Pipeline + Safety & Efficacy Data + Development Plan * Corporate

Slide 4: Company Overview
Company Overview Fully-Human Antibody | | MabVaxis an antibody discovery and development company with products that were Discovery Platform | discovered from the immune response of cancer patients Clinical stage Developmant Company | | Thee active Phase 1 clinica rials targeting CA19-9 positive mali

Slide 5: Management Team
Management Team J. David Hansen _ ; AVANIER Schering Pu feo shes Sub President, ceO and Chairman «AN AWM, DUT B® f “Gregory . Hanson, CMA, MBA piece MAST Chief Financial Otficer = Philip 0. Livingston, M.D. Chief Scientific officer anes apmn AAIPHARMA EM ARENA & Wand chet Busnes oficer — JSventat in

Slide 6: Board of Directors
Board of Directors Mi J, David Hansen President, CEO and Chairman of MabVax Jeffrey F. Eisenberg Former CEO Noven Pharmaceuticals, Former Acting Gen Counsel IVAX Jeffrey V. Ravetch, M.D., Ph.D. National Academy of Sciences and Institute of Medicine, Academy of Arts and Sciences and the American Asso

Slide 7: Human Antibody (HuMab) Discovery Platform
Human Antibody (HuMab) Discovery Platform Proprietary Approach to the Discovery and Development of Novel Fully Human Antibody Therapy and Diagnostic Agents Focused Discovery Screening Optimized Therapy Fully human antibody ‘minimizes immunogenicity. Binding sequence reflects the patient's immune sys

Slide 8: Scientific Rationale
\ ’ { Scientific Rationa Say Lewis (te), the Hua 561 tara, isexgrezedin over 90% of panereate snd + CA19 91s considered a vatable adjnctn the diagnos, prognosis and montoring of + steis densely expressed in mits of opy numbers on toget umors ae ae ee) [A Pancreatic; 8 Colon. Lung. Blader © ovanan; B

Slide 9: Radioimmunotherapy (RIT) is Lead Clinical Program
Radioimmunotherapy (RIT) is Lead Clinical Program Mi Antibody-Based Therapeutic Agent to Treat Very Difficult Cancers Such as Pancreatic, Small Cell Lung and Colon + Target significantly over, expressed on cancers « Antibody has high degree of Established safety, specifiy, specificity for tumors. ‘a

Slide 10: Pipeline
Vi Se Protram Discovery Lead Op__PresND__Phasex_——__Phase2 ‘SialylLewis*for Pancreatic Cancer and CA19-9 malignancies including Lung and Gl Cancers Radioimmunotherapy (MVT1075) a Therapeutic (MVT-5873): Monotherapy > ‘Therapeutic (MVT-5873): + Chemo —SEEEESSS ImmunoPET imaging (MVT-2163) SEE Ta for

Slide 11: Safety and Efficacy
Safety and Efficacy

Slide 12: ing of transient elev
ing of transient elev typically resolved within a week ions in ALT, AST and rubin that Infusion reactions were mitigated with pre-medication and extended infusion times The MTD was established at 1 mg/kg + Al (1mg/kg) dosed every second week ue Bee Be ‘Ad (1me/ke) dosed every week Clears use in comb

Slide 13: Inclusion Criteria Established for Future Clinical Trials
M Inclusion Criteria Established for Future Clinical Trials * Phase 1a identified “responder subset” with at least 50% reduction in CA19-9 levels after single agent treatment. The “responder subset”: Are patients at screening that had CA19-9 levels < 2500 U/mL Stayed on treatment 4 months versus 1 m

Slide 14: Scientific and Medical Rationale for Imaging and RIT Dosing Strategy
M Scientific and Medical Rationale for Imaging and RIT Dosing Strategy + Antibodies are processed in the liver and spleen which play a central role in antibody clearance + Administration of cold antibody first saturates clearance mechanisms and reduces accumulation in liver and spleen + Cold-Hot dos

Slide 15: Cold-Hot Dosing Strategy Reduces Liver and Spleen Accumulation
Cold-Hot Dosing Strategy Reduces Liver and Spleen Accumulation Mi Data Support Using the Cold-Hot Dosing Strategy for RIT Program MiP images of two patients illustrating decreased liver SUV after cold pre-dose at day 7 2 Sx Sow EY Cencerttonatepcetin § 104 ne & 0 #17 «47 re IL . u dpe verre ener SUV

Slide 16: HuMab-5B1 Specifically Targets CA19-9 Positive Tumor Lesions
HuMab-5B1 Specifically Targets CA19-9 Positive Tumor Lesions Focal radiotracer uptake above background was observed in primary tumors and metastases from day 2 and continuously increased through day 7 + Day 7 tumor SUV,,,, Were as high as 101 g/mL FOG PET SUV, values “10 g/mL. + High focal uptake wa

Slide 17: Clinical Development Plan of Lead Asset MVT-1075 (RIT)
Clinical Development Plan of Lead Asset MVT-1075 (RIT)

Slide 18: One Cycle of Treatment
) One Cycle of Treatment Day 1 * MVT-5873 Cold Dose # ~Ahours wait Day 15 * MVT-1075 Hot Dose Day 57 Safety monitoring visits throughout and dosimetry completed day 8 RIT (MVT-1075) Phase 1a Clinical Trial First-In-Human Phase 1 + Nonrandomized, open-label, dose- escalation (343 <esign) cohort expan

Slide 19: RIT (MVT-1075) Phase 1 Trial 2017
RIT (MVT-1075) Phase 1 Trial 2017 + Firstin-Human dose June 2017 + Primary Objectives + ive inden aes aa ole ret Determine the MTD and safety profile of MVT-S873 / MVT-1075 Honor Health (niated) and MSKCC (planned early 3) * Secondary Objectives: «+ Enroll ~6 patients in 2017 Evaluate tumor response

Slide 20: Financial and IP Snapshot
Mi NASDAQ Share Price* Market Cap* 3M Avg, Daily Volume* Common Stock Outstanding Preferred Stock {common equivalents with voting backer) Public Float Cash as of March 31, 2017! PIPE/Offering, net, May 2017 Financial and IP Snapshot MBVx $1.47 $12.8M 80.0K 87M 6.0M 83M $ 06M $ 43M + Key clinical ass

Slide 21: Milestones and News Flow
Milestones and News Flow | herapy| {Pree @aacr | Fle orphan Org | Interim softy & Phose 10 MTD Radioimmunotherapy | 7 pases bose Designation ‘hear AACR 0 ASCO Single Agent 7 Phase 1a @ ASCO ‘AACRNCLEORTE Chemo Combination Inter Safety AACRNCEORTE PET Imaging Agent HuMab-581 Fe Phage 10.6 SNM = ‘Aree

Slide 22: Radioimmunotherapy (MVT-1075) program guided by recent clinical experience
dS * Radioimmunotherapy (MVT-1075) program guided by recent clinical experience 50 patients in three active clinical investigations with the HuMab-5B1 Antibody Data from completion of two Phase 1 studies accelerates RIT program * Significant unmet medical need in cancers with poor prognosis + Large

Slide 23: MabVax Therapeutics
MabVa» therapeutics NASDAQ: MBVX ‘wirenabvatlae
Source: SEC EDGAR · 8-K filed Jun 23, 2017
More decks from MabVax Therapeutics Holdings Inc
Investor Presentation (October 2018)19 slides · Oct 22, 2018
Virtual Investor Conference (May 2018)25 slides · May 3, 2018
Investor Presentation (February 2018)24 slides · Feb 12, 2018
Investor Presentation (September 2017)33 slides · Sep 12, 2017
Investor Presentation (August 2017)33 slides · Aug 24, 2017
Technical Presentation (April 2017)57 slides · Apr 7, 2017